The precise role of 5′ AMP-activated kinase (AMPK) in cancer and its potential as a
therapeutic target is controversial. Although it is well established that activation of this …

Aim We carried out this meta-analysis on all published studies to estimate the overall cancer
risk of the use of metformin in T2DM patients. Methods We searched the PubMed, Embase …

Conventional chemotherapy is the main treatment for cancer and benefits patients in the
form of decreased relapse and metastasis and longer overall survival. However, as the …

Background Although prior studies showed metformin could reduce gastric cancer (GC) risk
in patients with diabetes mellitus, they failed to adjust for Helicobacter pylori infection and …

Helicobacter pylori (H. pylori) infection is the most important risk factor for gastric cancer
(GC) development through the Correa's gastric carcinogenesis cascade. However, H. pylori …

Metformin is a widely used antidiabetic drug, and there is evidence among diabetic patients
that metformin is a chemopreventive agent against multiple cancers. There is also evidence …

This retrospective cohort study investigated whether metformin may reduce gastric cancer
risk by using the reimbursement databases of the Taiwan's National Health Insurance …

The epidemiological literature suggests that insulin resistance, hyperinsulinemia, and
increased levels of insulin-like growth factors place patients with type 2 diabetes mellitus …

Objectives The objective of this study was to evaluate the association between metformin
therapy and the incidence of gastric cancer (GC) in patients with type 2 diabetes mellitus …

Diabetes mellitus type 2 and cancer share many risk factors. The pleiotropic insulin-
dependent and insulin-independent effects of metformin might inhibit pathways that are …